$SAVA So the problem I see is a long no man's land until phase 3 is completed... so it will bleed slowly as all biotechs do. Without catalysts which is the lifeblood of a price sustained institutions will want a low price to enter, and short it for an assured gain the way down until that point. Only suckers will hold long sadly. Hence the paradox of a life changing medication that can propel this stock to hundreds but in the short term a ride to the low 10s probably. Gotta love steal-street, The only way to survive is to move away now and come back in a year when it can be scooped up low for a 20-30X run.
8
2
2 Likes